Role of Matrix Metalloproteinase-2 in the Development of Cyclophosphamide-Induced Cardiomyopathy
- 24 Downloads
Immunohistochemical assay was employed to determine localization of MMP-2 in cardiomyocytes of WAG rats and changes in MMP-2 expression during modeled cardiomyopathy induced by single intraperitoneal injection of cyclophosphamide (125 mg/kg) alone or in combination with preventive intraperitoneal administration of an equal dose of asparcam-L (potassium-magnesium asparaginate) 30 min prior to the cytostatic. In the myocardium of control and experimental rats, MMP-2 was mostly located in cardiomyocyte nuclei. During the development of cyclophosphamide-induced cardiomyopathy (in 3 days after injection), the index of MMP-2-positive cardiomyocyte nuclei increased by 76%. In contrast to control hearts, MMP-2 was also expressed in the cardiomyocyte sarcoplasm. Preventive injection of asparcam-L moderated the cardiotoxic effect of cyclophosphamide, which manifested in less pronounced increase in the volume density of cardiomyocytes with lytic changes (by 42%) and index of MMP-2+ cardiomyocyte nuclei (by 23%) in comparison with the rats exposed to cyclophosphamide alone.
Key Words
cardiomyopathy cyclophosphamide matrix metalloproteinase-2 potassiummagnesium asparaginate immunohistochemistryPreview
Unable to display preview. Download preview PDF.
References
- 1.Kamyshnikov VS. Reference Book on Clinical and Chemical Laboratory Diagnostics. Vol. 2. Minsk, 2000. Russian.Google Scholar
- 2.Lushnikova EL, Nikityuk DB, Klinnikova MG, Koldysheva EV, Mzhel’skaya MM. Expression of matrix metalloproteinase-2 in the myocardium in the experimental model of anthracycline cardiomyopathy. Morfologiya. 2016;150(6):29-33. Russian.Google Scholar
- 3.Nepomnyashchikh LM, Lushnikova EL, Bakarev MA, Nikityuk DB, Yuzhik EI, Mzhelskaya MM, Nepomnyashchikh RD, Klinnikova MG, Karpova AA. Immunohistochemical Analysis of MMP-2 Expression in the Myocardium During the Postinfarction Period. Bull. Exp. Biol. Med. 2015;159(4):505-510.CrossRefPubMedGoogle Scholar
- 4.Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation. 2010;122(20):2039-2047.CrossRefPubMedPubMedCentralGoogle Scholar
- 5.Ali MA, Fan X, Schulz R. Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc. Med. 2011;21(4):112-118.CrossRefPubMedGoogle Scholar
- 6.Baghirova S, Hughes BG, Poirier M, Kondo MY, Schulz R. Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart. J. Mol. Cell. Cardiol. 2016;94:153-161.CrossRefPubMedGoogle Scholar
- 7.Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2007;292(4):H1847-H1860.CrossRefPubMedGoogle Scholar
- 8.Fan X, Hughes BG, Ali MA, Chan BY, Launier K, Schulz R. Matrix metalloproteinase-2 in oncostatin M-induced sarcomere degeneration in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2016;311(1):H183-H189.CrossRefPubMedGoogle Scholar
- 9.Gao L, Zheng YJ, Gu SS, Tan JL, Paul C, Wang YG, Yang HT. Degradation of cardiac myosin light chain kinase by matrix metalloproteinase-2 contributes to myocardial contractile dysfunction during ischemia/reperfusion. J. Mol. Cell. Cardiol. 2014;77:102-112.CrossRefPubMedGoogle Scholar
- 10.Hughes BG, Fan X, Cho WJ, Schulz R. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am. J. Physiol. Heart Circ. Physiol. 2014;306(5):H764-H770.CrossRefPubMedGoogle Scholar
- 11.Hughes BG, Schulz R. Targeting MMP-2 to treat ischemic heart injury. Basic Res. Cardiol. 2014;109(4):424. doi: https://doi.org/10.1007/s00395-014-0424-y.CrossRefPubMedGoogle Scholar
- 12.Jacob-Ferreira AL, Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: Consequences and therapeutic strategies in the heart. Arch. Biochem. Biophys. 2013;540(1-2):82-93.CrossRefPubMedGoogle Scholar
- 13.Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu. Rev. Pharmacol. Toxicol. 2007;47:211-242.CrossRefPubMedGoogle Scholar
- 14.Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc. Res. 2000;46(2):225-238.CrossRefPubMedGoogle Scholar
- 15.Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-López NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J. Mol. Cell. Cardiol. 2007;43(4):429-436.CrossRefPubMedGoogle Scholar